Overestimating the Benefit of Cancer Drugs

To the Editor Salas-Vega et al report that new cancer drugs approved between 2003 and 2013 improved overall survival (OS) by a mean of 3.43 months. This magnitude is greater than the median of 2.1 months reported by Fojo et al for drugs approved between 2002 and 2014 for solid tumors. Several observations may explain the difference.

http://ift.tt/2sU7zvz